Project Details Medicinal Chemistry in Drug Discovery and Development, India

Project No.:
2016-009-1-700
Start Date:
01 July 2016
End Date:
19 June 2018
Division Name:
Chemistry and Human Health Division
Division No.:
700

Objective

The objective of the Medicinal Chemistry/Drug Discovery & Development India (MCADDI) project is to continue to build and optimize a basic drug discovery course for industrial and academic scientists including Medicinal Chemists in India and other South Asian countries. The initial success of the program, partly supported by IUPAC grant in 2015 (project 2014-011-2-700) is one of the driving forces to continue our theme of applied chemistry education in relation to drug design and development.

Biocon Academy has generously agreed to host this event and will provide the access to their facility for the period. This 5-day course will enhance the program from the 2015 Course by adding new lectures to cover target validation/identification, high-throughput screening, DMPK and preclinical evaluation of toxicity that will be divided into two parts. The first part would be focused on fundamentals of Chemistry and Biology and the second part will be focused on the application of the current technology to the design and Development of druggable candidates. The 2017 program will also dedicate half a day session on Biologics principles and drugs candidates.

The increase in medicinal chemistry employment in Indian and southeast Asian pharmaceutical companies and in Contract Research Organizations (CROs) collaborating with US and European companies has created an ongoing need for chemists to acquire state of the art knowledge of medicinal chemistry. The performance and value of the MCADDI course will be assessed after three years, from the 2015 course and a decision whether to continue in the same format made at that time.

The desired outcome will be to enroll new and broader set of drug discovery scientists from industry and academia. The number of participants would be about 100 as in 2015 from academic and industry, and the goal is to provide them with a strong introduction to the fundamentals of medicinal chemistry as well as the current practice of Medicinal chemistry in drug discovery as applied with the advancement in tools such as computer based drug design and combinatorial synthesis. Continued support for this 3-year pilot study is important to sustain the success of the 2015 Course. We are planning to actively seek the participation of other emerging/developing/ countries such as Singapore, Malaysia, South Africa etc.

Description

The increase in medicinal chemistry employment in Indian and Southeast Asian pharmaceutical companies and in the Contract Research Organizations collaborating with US and European companies has created a need for chemists to acquire state-of-the-art knowledge of medicinal chemistry. This course will emphasize the design strategy that takes into account of the DMPK and toxicophore in small molecules as well as the fundamentals of Biologics and Development of Biologics drugs. The MCADDI course will be based on the successful first year program in 2015 and the Drew University Residential School on Medicinal Chemistry, taught annually since 1986 on the Drew University campus in Madison, New Jersey (https://www.drew.edu/resmed/). MCADDI will comprise 4.5 days of content, including 18-20 1-hour lectures on topics covering all aspects of medicinal chemistry from target selection and validate to hit identification, hit-to-lead chemistry, and lead optimization. New lectures on preclinical toxicity and clinical development will be added for the 2017 program.

In line with the current development in Biologics space in drug discovery, we will have a half a day session on Biologics topics. Four case history presentations of successful drug discovery programs will also be included. The Course in 2017 will be taught mainly by faculty from the US, with some local Indian faculty members also participating. The plan is to increase the number of Indian faculty members in subsequent years. The performance and value of the MCADDI course will be assessed after the end of the 3-year period, and a decision whether to continue in the same format made at that time. The desired outcome will be to enroll 80-100 attendees each year, and provide them with a strong introduction to the practice of medicinal chemistry in drug discovery.

Progress

Download the final program (3-page PDF) of the 2017 course.

Details about the MCADDI program is available at https://mcaddi.com

The next course will be coordinated in 2019 – see follow-up project 2018-006-1-700

Page last updated 19 June 2018